Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma скачать в хорошем качестве

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma What is the background of this study? CARTITUDE-1 is “a single arm study of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients with relapsed multiple myeloma (RRMM) refractory to both IMiD and proteasome inhibitor (PI) or with at least three prior lines of therapy and previously exposed to anti-CD38 monoclonal antibody (MoAb). While recently reported efficacy results of cilta-cel were encouraging, it is unknown how they compare with similar patients receiving conventional (non CAR-T) treatment.” In this video: Dr. Luciano Costa (University of Alabama at Birmingham, Birmingham, AL, USA) explains that this study used a contemporary U.S.-based dataset of patients with multiple myeloma refractory to anti-CD38 MoAb (MAMMOTH) to identify patients who would meet eligibility for CARTITUDE-1 and who received conventional therapy. Conclusions: The study found that in patients with RRMM beyond therapy with IMiD, PI, and anti-CD38 MoAb, treatment with cilta-cel is associated with higher response rates and superior progression-free survival and overall survival when compared to conventional treatment. _______________ Improving Lives Through Research and Patient Care In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License